Missing New Richmond man thought to be homicide victim, BCI says msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.
Bobby Farrell: 23-year-old New Richmond man found dead nearly a week after disappearance wlwt.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wlwt.com Daily Mail and Mail on Sunday newspapers.
Pierre, SD, USA / DRGNews
May 13, 2021 | 3:34 PM
A Cavour, South Dakota, man has been indicted by a federal grand jury for Attempted Production of Child Pornography, Attempted Enticement of a Minor Using the Internet, and Transfer of Obscene Material to a Minor.
David Robert Farrell, age 39, pled not guilty.
The Indictment alleges that on April 22, 2021, Farrell knowingly attempted to coerce a minor female to engage in sexually explicit conduct for the purpose of producing visual depictions. Such images would be then transported in interstate and foreign commerce with a computer. The Indictment also alleges that on or about April 27, 2021, Farrell knowingly traveled to engage in sexual conduct with the same minor. Farrell again used his cellular telephone to attempt to knowingly persuade that minor to engage in sexual activity. Finally, the Indictment alleges that between April 22, 2021, and April 23, 2021, Farrell also used his cellular telephone to transfer and attempt to tran
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Claritas Announces Agreement with CMAX Clinical Research for Phase 1 Clinical Study of R-107
Claritas Pharmaceuticals, Inc.April 21, 2021 GMT
SAN FRANCISCO and TORONTO, April 21, 2021 (GLOBE NEWSWIRE) Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “Company” or “Claritas”) today announced that it has entered into an agreement with CMAX Clinical Research Pty Ltd (“CMAX”) to conduct a randomized, placebo-controlled, single-blind, single ascending dose Phase 1 clinical study to evaluate the pharmacokinetics and safety profile of the Company’s novel, liquid, nitric oxide-releasing drug, R-107.